Study to Evaluate the Safety and Efficacy of KITE-585 in Participants With Relapsed/Refractory Multiple Myeloma

Key Inclusion Criteria:

Measurable relapsed or refractory myeloma as defined by the International Myeloma Working Group (IMWG) Consensus Criteria following treatment with at least 3 lines of therapy including with both a proteasome inhibitor (PI) and an immunomodulatory drug (IMiD), or progressive myeloma that is refractory to a regimen containing both a PI and an IMiD.
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

Adequate bone marrow, renal, hepatic, pulmonary, and cardiac function defined as:

Absolute neutrophil count (ANC) ≥ 1,000/µL
Platelet count ≥ 75,000/µL
Absolute lymphocyte count ≥ 100/µL
Creatinine clearance above limits set in the protocol for each cohort
Normal cardiac function as assessed by electrocardiogram (ECG) and echocardiogram
Baseline oxygen saturation > 92% on room air and no clinically significant pleural effusion

Key Exclusion Criteria:

Plasma cell leukemia
Non-secretory multiple myeloma
History of Central nervous system (CNS) involvement by multiple myeloma
Prior CAR therapy or other genetically modified T cells
Inadequate washout from prior therapy
Autologous stem cell transplant within 6 weeks before enrollment or any history of allogenic transplant
History of active autoimmune disease
History of deep vein thrombosis or pulmonary embolism requiring systemic anticoagulation within 6 months before enrollment
Recent history of other (non multiple myeloma) cancer
Active viral, fungal, bacterial or other infection

Note: Other protocol defined Inclusion/Exclusion criteria may apply